mRNA at the FDA crossroads: science meets politics

The US Food and Drug Administration faces a Wednesday deadline to decide whether to approve Moderna’s mRNA-based influenza vaccine — what would be the first mRNA flu shot to reach market. The path here has not been smooth. In February, the FDA initially refused to review the vaccine’s application, departing from earlier assurances to Moderna that the submission would proceed. The move shook the pharmaceutical industry. A little over a week later, the FDA reversed course and agreed to review, after Moderna committed to conducting a confirmatory study if approved. In June, an FDA advisory panel recommended approval. The Department of Health and Human Services under Secretary Robert F. Kennedy Jr. cancelled nearly $500 million in mRNA vaccine research funding last year. The FDA operates under a political appointee — the HHS Secretary — who has publicly questioned mRNA technology’s value. Moderna president Stephen Hoge has said the company is holding off on some planned mRNA research pending the outcome. Smaller biotechs and venture capital firms have reportedly been spooked, affecting the broader landscape of mRNA research into conditions ranging from Lyme disease to rare cancers.

The received wisdom

The standard progressive framing is, at its core, a story about anti-science capture of regulatory agencies. The argument: mRNA technology represents a genuine medical breakthrough, demonstrated most dramatically by the COVID-19 vaccines that prevented millions of deaths; RFK Jr. represents a fringe ideology that has gained, through political accident, extraordinary institutional power; and the combination of the funding cuts and the FDA’s February backtrack signals a chilling effect on innovation that will cost lives. The story of Janusz Racz — a 69-year-old cancer patient in London who credits an mRNA clinical trial with eliminating his inoperable lung cancer — is not an anecdote but a synecdoche: the research pipeline that might produce such treatments is being iced by ideology. That framing draws on a solid empirical foundation. The broader mRNA research ecosystem — covering personalised cancer vaccines, HIV, respiratory syncytial virus, and rare diseases — depends on the FDA being a reliable and consistent regulator, and the FDA’s February flip-flop was, by most accounts, a departure from normal procedure that had no clear scientific justification.

A different read

The received framing is largely right on the science — mRNA technology’s safety and efficacy profile is well-established — but it elides a set of questions that a conservative, and specifically a Burkean, reading of regulatory governance would take seriously.

The first is about institutional process, not ideology. The FDA’s February reversal was not driven by new scientific data. It was driven by political pressure from the HHS Secretary’s office. The subsequent re-reversal — agreeing to review after the outcry — was driven by industry pressure and reputational concern. Neither move was driven by science. A regulator that bends to political pressure in one direction is also susceptible to bending in the other. If you celebrate the FDA’s capitulation to industry outrage in February, you are implicitly endorsing a regulatory model where institutional authority follows public relations battles. That is a fragile foundation, and it cuts both ways.

The second question concerns the specific regulatory ask. The FDA’s initial refusal to review was apparently triggered by a concern that Moderna had not provided sufficiently robust post-market evidence commitments. The requirement of a confirmatory study — which Moderna eventually agreed to — is not an unreasonable demand; it is how drug approval has worked for decades, and the accelerated authorisation model deployed for COVID vaccines was always presented as an emergency exception that would be validated by subsequent data. RFK Jr.’s scepticism of mRNA technology is, in its most credulous form, a garbled version of a legitimate concern: that platforms approved rapidly under emergency conditions should face rigorous post-market surveillance. His proposed remedy — cutting funding and questioning the platform wholesale — is wildly disproportionate and scientifically illiterate. But the underlying instinct that emergency-era procedures should not become permanent norms is not, in itself, anti-science.

The third issue is the economic ecosystem. Jeff Coller of Johns Hopkins has pointed out that Moderna is a large firm with the resources to absorb FDA uncertainty; the small biotechs — companies of twenty or thirty employees working on mRNA applications for rare diseases — cannot. The funding cuts and regulatory instability are most damaging not to the giants but to the research layer below them, where the highest-risk, highest-reward science happens. This is a classic case of regulations and fiscal decisions that nominally affect an industry equally but in practice consolidate power with incumbents. Moderna can wait; the start-up with a promising Lyme disease vaccine cannot. If the conservative movement is serious about competition and against regulatory capture by incumbents, it should be more concerned about this than it currently appears to be.

There is a genuine tension in the conservative position on this question. Scepticism of technocratic expertise is a legitimate intellectual tradition — from Michael Oakeshott’s critique of rationalism in politics to the public choice economists’ analysis of regulatory capture. But that scepticism should produce demands for better institutions, not for weaker ones. An FDA that is bullied by an ideologically motivated cabinet secretary is not a more accountable FDA; it is a more politically captured FDA. The goal should be a robust, independent, technically rigorous FDA that is insulated from both industry lobbying and presidential preference. What is currently happening is the opposite.

What to watch

The Wednesday deadline is the immediate marker: watch whether the FDA approves, rejects, or requests further time. An approval would signal that institutional process has, barely, held; a rejection on non-scientific grounds would confirm that the FDA has been effectively subordinated to HHS ideology. Watch also whether the small biotech sector’s current paralysis — described by investors and company founders as an investment freeze — begins to lift or deepen after the decision. A market signal — stock movements in the mRNA space — will be an immediate read. Longer term, watch whether Congress moves to codify FDA independence in statute, a step that has been discussed for years and has gathered more urgency in recent months.

— J